It is suggested that melanoma patients with high immunogenicity (including a high content of immune infiltrating cells, high expression of PD-L1, and high concentration of immune cytokines) and high tumor mutation burden are at a low risk and can benefit more from immunotherapy to achieve prolonged survival [38]. This evidence concerns the gene CD274 and neoplasm.